Takeda’s vaccines business could be a big part of the company’s future growth thanks to a promising late-stage Dengue vaccine candidate and partnerships with Moderna and Novavax on their COVID-19 shots in Japan.
Takeda To Build On COVID-19 Awareness For Its Dengue Vaccine
TAK-003 Could Be Blockbuster
Takeda’s vaccines chief Rajeev Venkayya tells Scrip about its COVID-19 vaccines partnerships, and how the pandemic can stimulate action against other infectious disease threats such as Dengue.
